NIDA and ARC announce funding opportunity for research projects to address opioid injection use and its consequences in the Appalachian Region
February 25, 2016
The National Institute on Drug Abuse (NIDA), in partnership with the Appalachian Regional Commission (ARC), has announced a NIDA funding opportunity for one-year, services planning research grants to address a dramatic increase in adverse outcomes associated with increased opioid injection drug use in Appalachia. The grants will help develop an epidemiologic understanding of opioid injection drug use, HIV and hepatitis C virus (HCV) infection risk, and other adverse health consequences of drug use in any of the 420 Appalachian counties (http://www.arc.gov/counties).
This research should provide the foundation for future intervention programs and larger scale research efforts to enable improved, research-driven interventions that can address these critical public health threats in the rural Appalachian context. Findings should help enable access to screening and treatment and improve access to well-integrated clinical, public health, and social services which address these conditions in rural and economically distressed settings.
Challenging health trends in these communities include: broad geographic health disparities; the region’s traditional reliance on natural resource extraction and other industry sectors which require extensive physical labor; high rates of injury and disability requiring pain management; historically high rates of prescription opioid drug use; barriers to the delivery of primary care and mental health services; and other cultural and socio-economic conditions which influence health behaviors.
Applicants for research funding are encouraged to identify a discrete target area consisting of one or more Appalachian counties, and to engage community-based stakeholders’ cooperation in the provision of information, feedback and data necessary for the successful implementation of the research.
Grants will be administered by NIDA. Applications are due by April 28, 2016, by 5:00 pm local time of applicant organization. http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-16-015.html#_Section_I._Funding.
For more information, contact the NIDA press office at media@nida.nih.gov or 301-443-6245.
Contact:
NIDA Press Office
301-443-6245
media@nida.nih.gov
About the National Institute on Drug Abuse (NIDA): The National Institute on Drug Abuse (NIDA) is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. Fact sheets on the health effects of drugs and information on NIDA research and other activities can be found at www.drugabuse.gov, which is now compatible with your smartphone, iPad or tablet. To order publications in English or Spanish, call NIDA’s DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or email requests to drugpubs@nida.nih.gov. Online ordering is available at drugpubs.drugabuse.gov. NIDA’s media guide can be found at www.drugabuse.gov/publications/media-guide/dear-journalist, and its easy-to-read website can be found at www.easyread.drugabuse.gov. You can follow NIDA on Twitter and Facebook.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH. . .Turning Discovery Into Health®